{"id":"amisulpride-add-on","safety":{"commonSideEffects":[{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Parkinsonism"},{"rate":null,"effect":"Prolactin elevation"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amisulpride preferentially antagonizes dopamine receptors in the mesolimbic and mesocortical pathways at low doses, with activity at D2 receptors predominating. At higher doses, it also blocks D3 receptors. As an add-on therapy, it is used to augment antidepressant or antipsychotic effects in patients with inadequate response to monotherapy.","oneSentence":"Amisulpride is a selective dopamine D2/D3 receptor antagonist that blocks dopamine signaling in the brain to reduce psychotic symptoms and improve mood.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:42:23.982Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Augmentation therapy for major depressive disorder with inadequate response to antidepressants"},{"name":"Augmentation therapy for schizophrenia or other psychotic disorders"}]},"trialDetails":[{"nctId":"NCT02926859","phase":"PHASE2","title":"Enhancing Recovery in Early Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2017-04-08","conditions":"Schizophrenia","enrollment":180},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT01105481","phase":"PHASE4","title":"Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2006-05","conditions":"Treatment-resistant Schizophrenia","enrollment":273}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Amisulpride add-on","genericName":"Amisulpride add-on","companyName":"National Health Research Institutes, Taiwan","companyId":"national-health-research-institutes-taiwan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amisulpride is a selective dopamine D2/D3 receptor antagonist that blocks dopamine signaling in the brain to reduce psychotic symptoms and improve mood. Used for Augmentation therapy for major depressive disorder with inadequate response to antidepressants, Augmentation therapy for schizophrenia or other psychotic disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}